Approval · Notice of Compliance 26022 · 2021
LEDAGA: Notice of Compliance 26022
Issued June 8, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26022
- Date
- June 8, 2021
- Company
- Recordati Rare Diseases Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LEDAGA | 02516764 | Marketed |
Medicinal ingredients
- CHLORMETHINE 160 MCG per G